Boehringer Ingelheim's China-developed CSF live vaccine approved

Ingelvac CSF MLV will be produced by company's Taizhou plant, and it is expected to be commercialized in early 2021.

June 25, 2020

2 Min Read
Boehringer Ingelheim's China-developed CSF live vaccine approved
China Photos/Getty Images

Boehringer Ingelheim is proud to announce that its China-developed classical swine fever live vaccine (C-strain, PK/WRL Cell Line Origin) (English trade name: Ingelvac CSF MLV) has recently obtained a "New Veterinary Drug Registration Certificate" from the Ministry of Agriculture and Rural Affairs of China. It is the first CSF live vaccine jointly developed by a multinational company and Chinese research institutes. It marks another milestone for Boehringer Ingelheim's "in China, for China," as the company is committed to providing innovative and high-quality swine vaccines for the Chinese swine industry, as well as holistic swine disease solutions to pig farms.

CSF is a highly contagious and lethal infectious disease in pigs. As the disease has caused huge economic losses to the pig farming industry, it is classified as Class A Animal Disease in China. Even though massive vaccination with CSF live vaccines in China are effectively controlling the outbreak of CSF, endemic and sporadic spread still exists.

Most CSF live vaccines currently available on the market can only be stored at -15 degrees Celsius for 18 months. Cold-chain transportation, storage and dilution all need a strict temperature control. The newly approved Ingelvac CSF MLV uses state-of-the-art microcarrier-based suspension culture and freeze-drying technologies to ensure high-titer virus, stable vaccine production process and controllable quality. It can be stored at 2 to 8 degrees Celsius for 24 months. 

Ingelvac CSF MLV will be produced by Boehringer Ingelheim's Taizhou plant, Jiangsu province, and it is expected to be commercialized in early 2021. It will become Boehringer Ingelheim's first swine vaccine product, developed, manufactured and distributed in China. The Taizhou plant already manufactures Ingelvac PRRS MLV (live vaccine for porcine reproductive and respiratory syndrome).

Source: Boehringer Ingelheim, which is solely responsible for the information provided, and wholly owns the information. Informa Business Media and all its subsidiaries are not responsible for any of the content contained in this information asset.

Subscribe to Our Newsletters
National Hog Farmer is the source for hog production, management and market news

You May Also Like